Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P B Huber

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Pharmaceutical Sciences|June 1, 1978
Bioequivalence and interchangeabilityS Hwang, P B Huber, M Hesney, et al.
Digestive Diseases and Sciences|December 1, 1985
MK-208, a novel histamine H2-receptor inhibitor with prolonged antisecretory effectR W McCallum, A N Chremos, B Kuljian, et al.
Clinical Pharmacology and Therapeutics|September 1, 1980
Comparison of oral indacrinone with furosemideJ D Irvin, P H Vlasses, P B Huber, et al.
Clinical Pharmacology and Therapeutics|July 1, 1982
Effects of enalapril, a new converting enzyme inhibitor, in hypertensionR K Ferguson, P H Vlasses, B N Swanson, et al.
Clinical Pharmacology and Therapeutics|December 1, 1982
Timolol and propranolol: bioavailability, plasma concentrations, and beta blockadeT W Wilson, W B Firor, G E Johnson, et al.
Clinical Pharmacology and Therapeutics|September 1, 1981
Effect of antacids on the bioavailability of diflunisal in the fasting and postprandial statesJ A Tobert, P DeSchepper, T B Tjandramaga, et al.
Clinical Pharmacology and Therapeutics|June 1, 1981
Pharmacology of enantiomers and (-) p-OH metabolite of indacrinoneP H Vlasses, J D Irvin, P B Huber, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Pharmaceutical Sciences|June 1, 1978
Bioequivalence and interchangeabilityS Hwang, P B Huber, M Hesney, et al.
Digestive Diseases and Sciences|December 1, 1985
MK-208, a novel histamine H2-receptor inhibitor with prolonged antisecretory effectR W McCallum, A N Chremos, B Kuljian, et al.
Clinical Pharmacology and Therapeutics|September 1, 1980
Comparison of oral indacrinone with furosemideJ D Irvin, P H Vlasses, P B Huber, et al.
Clinical Pharmacology and Therapeutics|July 1, 1982
Effects of enalapril, a new converting enzyme inhibitor, in hypertensionR K Ferguson, P H Vlasses, B N Swanson, et al.
Clinical Pharmacology and Therapeutics|December 1, 1982
Timolol and propranolol: bioavailability, plasma concentrations, and beta blockadeT W Wilson, W B Firor, G E Johnson, et al.
Clinical Pharmacology and Therapeutics|September 1, 1981
Effect of antacids on the bioavailability of diflunisal in the fasting and postprandial statesJ A Tobert, P DeSchepper, T B Tjandramaga, et al.
Clinical Pharmacology and Therapeutics|June 1, 1981
Pharmacology of enantiomers and (-) p-OH metabolite of indacrinoneP H Vlasses, J D Irvin, P B Huber, et al.
Pageof 1